Dear Patients and Families,
Welcome to the UNC bleeding disorders, HHT and thrombosis program’s website. We hope you find this information useful in answering questions and learning about our center.
I am privileged to lead an innovative and dedicated group of professionals who are committed to enhancing the health and quality of life of people with bleeding and clotting disorders through comprehensive health care services, education, and research. Throughout its long history, the UNC Hemophilia and Thrombosis Center has been the core of ground-breaking research achievements and clinical care to benefit patients and their families.
We are happy to be back in clinic and are encouraging in-person visits. We look forward to seeing you, and as always, please contact us at the phone numbers below.
We want you all to be safe and we are here for you.
Sincerely,
Nigel Key, MD
Our News
-
Normal operations
The HTC is operating under normal conditions. Stay tuned to NBDF (https://www.bleeding.org/advocacy), HFA (https://www.hemophiliafed.org/our-work/advocate/), and BDFNC (https://bleedingdisordersnc.org/programs-events/advocacy/) for updates on advocacy and government affairs.
-
Hemofil M & Recominate discontinuing mid 2026
Takeda stated it would continue to supply both medications to current patients until inventory is depleted or expires in mid-2026. If you rely on one of these products, please reach out to your specialty pharmacy with any questions. You should have received a letter in the mail also. More information can be found at: https://www.bleeding.org/news/breaking-news-takeda-announces-discontinuation-of-two-hemophilia-treatments.
-
Hurricane Helene Resources
We are very concerned for those impacted by the historic flooding and devastation caused by Hurricane Helene. We hope all are safe. Please reach out to us via phone or mychart if there is anyway we can help or be of assistance. Please see these links for support and help, ways to donate to those … Read more
-
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer’s gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. Quick article for more information!
Follow Us